Top of the morning to you, and a fine one it is. After all, there are birds chirping by our window and a cool breeze is wafting by. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Our choice today is chocolate raspberry, a yummy treat. Remember, no prescription is required. Meanwhile, here are a few items of interest. Have a grand day, and drop us a line if you hear something saucy. …
Walmart plans to help drug companies and contract research organizations identify and recruit individuals to fill their clinical trials, pitting it against Walgreens and CVS Health, Reuters tells us. Walmart Healthcare Research Institute, the retailer’s new health care research service, will find participants for clinical trials, and Walmart will also host MyHealthJourney, a patient portal that helps people find upcoming research trials and track their care. Walgreens said in June it had launched clinical trial services to increase diversity in test subjects and CVS Health began offering clinical trials in 2021.
Viatris is considering a potential sale of its consumer-health assets in Europe, in a deal that could fetch more than $2.9 billion, according to Bloomberg News. The assets could draw interest from large private equity firms with existing over-the-counter businesses or strategic suitors seeking to grow their business in the region. Viatris was created from the merger of Mylan and the Upjohn unit at Pfizer in 2020, and is known for its off-patent blockbuster brands such as the Lipitor cholesterol pill, the Viagra erectile dysfunction drug, and the Zoloft antidepressant. Its lesser-known, over-the-counter products include dietary supplements, like iron, allergy medicines, and cosmetics.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect